Protein microarrays for quantitative detection of PAI-1 in serum

Chinese Journal of Cancer Research

Volumn 24, Issue 3, 2012, Pages 220-225

  Ma, Xu ^a   Zhang, Qing Yun ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Breast cancer; Plasminogen activator inhibitor 1; Protein microarray; Serum

Indexed keywords

ESTROGEN RECEPTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADOLESCENT; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; FEMALE; FLUORESCENCE; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN MICROARRAY; QUANTITATIVE ANALYSIS; SCREENING TEST; TUMOR LOCALIZATION;

EID: 84865198082     PISSN: 10009604     EISSN: 19930631     Source Type: Journal    
DOI: 10.1007/s11670-012-0220-x     Document Type: Article

References (20)

1. Durand MK, Bodker JS, Christensen A, et al. Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis. Thromb Haemost 2004; 91:438-49. (Pubitemid 38396865)
2. Look MP, van Putten WL, Duffy MJ, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002; 94:116-28. (Pubitemid 34121291)
3. Grebenchtchikov N, Maguire TM, Riisbro R, et al. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration. Oncol Rep 2005; 14:235-9.
4. Palmirotta R, Ferroni P, Savonarola A, et al. Prognostic value of presurgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer. Thromb Res 2009; 124:403-8.
5. Seong SY, Choi CY. Current status of protein chip development in terms of fabrication and application. Proteomics 2003; 3:2176-89.
6. Zhu H, Snyder M. Protein chip technology. Curr Opin Chem Biol 2003; 7:55-63. (Pubitemid 36126493)
7. Templin MF, Stoll D, Schrenk M, et al. Protein microarray technology. Trends Biotechnol 2002; 20:160-6. (Pubitemid 34242857)
8. Weissenstein U, Schneider MJ, Pawlak M, et al. Protein chip based miniaturized assay for the simultaneous quantitative monitoring of cancer biomarkers in tissue extracts. Proteomics 2006; 6:1427-36.
9. Chen H, Jiang C, Yu C, et al. Protein chips and nanomaterials for application in tumor marker immunoassays. Biosens Bioelectron 2009; 24:3399-411.
10. Ren F, Zhang QY, Wang YM, Xu JJ. Cloning of human plasminogen activator inhibitor-1 (PAI1) gene and preparation of its monoclonal antibodies as well as its application in detection of PAI1 expression in breast cancer cells. Zhonghua Jian Yan Yi Xue Za Zhi (in Chinese) 2007; 11:1274-8.
11. Gonzalez RM, Seurynck-Servoss SL, Crowley SA, et al. Development and validation of sandwich ELISA microarrays with minimal assay interference. J Proteome Res 2008; 7:2406-14.
12. Kambhampati D. Protein Microarray Technology. Weinheim: WILEYVCH, 2003.
13. Angleton P, Chandler WL, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation 1989; 79:101-6. (Pubitemid 19043680)
14. Demirkan B, Ozcan MA, Glu AA, et al. The effect of anthracycline-based (epirubicin) adjuvant chemotherapy on plasma TAFI and PAI-1 levels in operable breast cancer. Clin Appl Thromb Hemost 2006; 12:9-14. (Pubitemid 43221566)
15. Herszényi L, Farinati F, Cardin R, et al. Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer. BMC Cancer 2008; 8:194.
16. Becker M, Szarvas T, Wittschier M, et al. Prognostic impact ofvv plasminogen activator inhibitor type 1 expression in bladder cancer. Cancer 2010; 116:4502-12.
17. Langenskiöld M, Holmdahl L, Angenete E, et al. Differential prognostic impact of uPA and PAI-1 in colon and rectal cancer. Tumour Biol 2009; 30:210-20.
18. Angenete E, Langenskiöld M, Palmgren I, et al. uPA and PAI-1 in rectal cancer-relationship to radiotherapy and clinical outcome. J Surg Res 2009; 153:46-53.
19. Yamada Y, Arao T, Matsumoto K, et al. Plasma concentrations of VCAM- 1 and PAI-1: a predictive biomarker for post-operative recurrence in colorectal cancer. Cancer Sci 2010; 101:1886-90.
20. Vaughan DE, De Taeye BM, Eren M. PAI-1 antagonists: predictable indications and unconventional applications. Curr Drug Targets 2007; 8:962-70. (Pubitemid 47578144)